Next Article in Journal
Correction of Post-Surgical Temporal Hollowing with Adipo-Dermal Grafts: A Case Series
Previous Article in Journal
The Impact of Diet-Induced Weight Loss on Inflammatory Status and Hyperandrogenism in Women with Polycystic Ovarian Syndrome (PCOS)—A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 16
10.3390/jcm13164935
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Could Obesity Be Related to the Increasing Incidence of Warthin Tumors?

by
Michał Gontarz
1,*,
Jakub Bargiel
1,
Krzysztof Gąsiorowski
1,
Tomasz Marecik
1,
Paweł Szczurowski
1,
Andrei Hramyka
2,
Joanna Kuczera
2,
Agata Wieczorkiewicz
2 and
Grażyna Wyszyńska-Pawelec
1
1
Department of Cranio-Maxillofacial Surgery, Jagiellonian University Medical College, 30-688 Cracow, Poland
2
Students’ Scientific Group of the Department of Cranio-Maxillofacial Surgery, Jagiellonian University Medical College, 30-688 Cracow, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(16), 4935; https://doi.org/10.3390/jcm13164935
Submission received: 29 July 2024 / Revised: 8 August 2024 / Accepted: 15 August 2024 / Published: 21 August 2024
(This article belongs to the Section Oncology)
Browse Figures
Versions Notes

Abstract

:
Background: The number of patients diagnosed with Warthin tumors (WTs) has increased significantly in recent years. The association of obesity as measured by body mass index (BMI) with the incidence of WTs remains unclear. This retrospective study aims to compare the BMI and other clinical factors of patients diagnosed with WTs to those with other benign epithelial parotid gland tumors. Methods: Over a 24-year period, 465 cases of benign epithelial parotid gland tumors were treated in our department. Of these, 155 (33.3%) were diagnosed as WTs. The results of the WT group were compared with those of another benign epithelial parotid gland tumor. Results: The mean BMI of WT patients was 27.3, which was significantly higher than in other benign tumors (25.52; p < 0.001). Furthermore, statistically significant correlations were observed, including a higher incidence of WT in males (p < 0.001), in the elderly (p < 0.001), and in cigarette smokers (p < 0.001). Additionally, a higher prevalence of other head and neck cancers was confirmed in patients with WTs (p = 0.004); Conclusions: This study supports the multifactorial etiology of WT development. Among these factors, smoking, advanced age, and obesity have been identified as factors associated with the development of WT, which might be due to chronic inflammation linked to obesity.

1. Introduction

Adenolymphoma, cystadenolymphoma, or papillary cystadenoma lymphomatosum was first described in 1895 by Hildebrand as a congenital cyst of the neck [1]. The term “papillary cystadenoma” was subsequently proposed by Albrecht and Artz in 1910 [2]. In 1929, American pathologist Aldred Scott Warthin described two additional cases in the English literature and introduced the term “papillary cystadenoma lymphomatosum” [3]. Since then, this tumor has been known as Warthin’s tumor (WT). WT is the second most common benign tumor of the salivary glands. WT is most commonly observed in the tail of the parotid gland. An extraparotid manifestation is uncommon and frequently involves nodes proximate to the parotid gland, particularly in neck level II [4,5].
Microscopically, WTs are composed of two components that vary in proportion from case to case. The first component is the true neoplastic oncocytic bilayered epithelium, which grows in cystic, solid, and papillary patterns. The second component is reactive stromal lymphoid tissue, often with lymph follicles present [6]. The epithelial and lymphoid components of WT may undergo malignant transformation, although this is a rare entity [7]. Additionally, the lymphoid components of WT may serve as a site for tumor-to-tumor regional and distant metastasis [8,9].
The number of patients diagnosed with WT has increased significantly in recent years [10,11,12]. Cigarette smoking is the only confirmed risk factor for the development of WT. Other explanations for the rise in incidence could be longer lifespan (senescent cells), improved diagnostic tools and imaging sensitivity, radiation exposure, chronic inflammation, metabolic dysfunction of mitochondria and Epstein–Barr virus, human papilloma virus (HPV) infection, or IgG4-related disease (IgG4-RD) [6,13,14]. In patients with oncological conditions, particularly in the context of PET/CT imaging, WT may be identified as an incidental tumor. Conversely, as evidenced by the study by Kadletz et al., the elevated prevalence of obesity may also be associated with a higher incidence of WT [15]. However, the association between high body mass index (BMI) and WT risk has not been confirmed by other reports in the literature. Furthermore, there is a lack of a multivariable analysis of BMI in comparison to other clinical factors influencing the incidence of WT.
This retrospective study aims to compare the BMI and other clinical factors of patients diagnosed with WT to those with other benign epithelial parotid gland tumors.

2. Materials and Methods

Between January 2000 to December 2023, 668 patients were treated for parotid gland tumors in the Department of Cranio-Maxillofacial Surgery of the Jagiellonian University in Cracow.
Patients with benign epithelial tumors of the parotid gland were included in this study. Patients operated upon due to malignant tumors—such as salivary gland cancers, lymphomas or metastases to the parotid gland—were excluded from the study. Additionally, benign nonepithelial tumors (lipoma, hemangioma, Schwannoma) and tumor-like lesions of the parotid gland (cysts, chronic inflammations, benign lymphoepithelial lesion, IgG4-related disease, sclerosing polycystic adenosis, Sjögren’s syndrome, tuberculosis, oncocytic metaplasia, cat scratch disease, and toxoplasmosis) were excluded (Figure 1).
The tumors were benign epithelial salivary gland neoplasms in 465 cases, 155 (33.3%) of which were diagnosed as WT. The medical charts of the patients were evaluated according to demographic characteristics, histopathological aspects, diameter and site of the tumor, smoking habits, BMI, and synchronous and metachronous tumors in head and neck region. BMI was assessed secondarily using the patient’s weight and height recorded on admission to the department prior to planned surgical treatment. The results of the WT group were compared with those of other benign epithelial parotid gland tumors, and the differences in terms of multifocal, bilateral, and extraparotid WTs were also assessed.
This study was approved by the institutional review board. As only medical files were obtained, the review board approved this study without the need for patient consent as long as all personal information was kept confidential and any facial features or other identifying marks were removed and/or covered.
Comparison of the values of qualitative variables within groups was performed using the chi-square test (with Yates adjustment for 2 × 2 tables) or Fisher’s exact test when the assumptions of the chi-square test regarding expected numbers were not met. Comparisons of quantitative variables in the two groups were made using the Mann–Whitney test. Multivariable analysis of the effect of potential predictors on a dichotomous variable (i.e., taking only two possible values—WT or other tumors) was performed using logistic regression. The results were rearranged in the form of OR (odds ratio) parameters along with 95% confidence intervals. The analysis assumed a significance level of 0.05. Thus, all p-values below 0.05 were interpreted as indicating significant relationships. The analysis was performed using R software, version 4.4.0.

3. Results

3.1. WT vs. Epithelial Benign Parotid Tumors

Table 1 shows the differences between the groups of patients with WT and other epithelial benign parotid tumors. Statistically significant correlations were observed, such as a higher incidence of WT in males (p < 0.001), the elderly (p < 0.001), and cigarette smokers (p < 0.001). A higher prevalence of other head and neck cancers (p = 0.004) and higher BMI (p < 0.001) was also confirmed in patients with WT.
In the multivariable logistic regression analysis of patients with benign parotid tumors (Table 2), it was found that
-
each additional year of age increases the odds of a WT by 9.4% (OR = 1.094);
-
female gender decreases the odds of WT by 59.5% (OR = 0.405) compared to male gender;
-
presence of another head and neck cancer increases the odds of WT by 5.713 times (OR = 5.713);
-
each additional kg/m2 in BMI increases the odds of WT by 12.1% (OR = 1.121);
-
smoking up to 10 cigarettes, 10–20 cigarettes, and more than 20 cigarettes per day increases the odds of WT by 5.136 (OR = 5.136), 14.014 (OR = 14.014) and 34.526 times (OR = 34.526), respectively.

3.2. Unifocal vs. Multifocal Parotid WT

Analysis of the relationship between patients with single WT and multiple WT showed no statistically significant relationship. BMI was comparable in both groups (p = 0.497) (Table 3).

3.3. Unilateral vs. Bilateral WT

Comparison of the group of patients with bilateral and unilateral WT revealed a statistically significant higher percentage of patients who smoked more and had bilateral tumors (p = 0.038). BMI was also comparable in both groups (p = 0.786) (Table 4).

3.4. Extraparotid vs. Intraparotid WT

In eight cases, extraparotid WT was found in cervical lymph node levels II and III (Figure 2). When comparing the groups of patients with parotid and extraparotid localization, there were also no statistically significant differences between these groups (Table 5). However, there was an apparent trend toward a higher incidence of extraparotid WT in the obese group (p = 0.08) and at a younger age (p = 0.095).

4. Discussion

Obesity is a chronic, progressive, and recurrent condition that leads to numerous adverse health, psychological, social, and economic consequences. According to the World Obesity Federation Annual Report 2020, the global prevalence of obesity is projected to increase from 11.4% in 2010 to 17.5% by 2030, with over 1 billion people expected to be living with obesity by then. At that time, one in five women and one in seven men will be obese [16]. Additionally, life expectancy is predicted to decrease by 0.9–4.2 years in the Organization for Economic Cooperation and Development (OECD), Group 20 (G20), and European Union (EU28) countries over the next 30 years [17].
Adipose tissue cells secrete adipokines and cytokines, which attract immune cells and promote a pro-inflammatory condition. Obesity-associated inflammation is first triggered by excess nutrients and is primarily localized in specialized metabolic tissues such as white adipose tissue. However, this low-grade inflammatory response associated with obesity leads to changes in immune cell infiltration and polarization not only in white adipose tissue but also in other organs, resulting in systemic inflammation [18,19,20]. Obesity also activates numerous oncogenic signaling pathways that promote tumor cell survival, proliferation, and metabolism. It is also worth noting that inflammation associated with obesity can be found in the salivary glands. Lehmann et al. observed an increased level of inflammatory markers in saliva in obese patients, including tumor necrosis factor-α receptors 1 and 2 (TNF-α-R1, TNF-α-R2), pentraxin 3 (PTX-3), interleukin 15 (IL-15), monocyte chemoattractant protein 1 (MCP-1), and soluble intercellular adhesion molecule 1 (slCAM-1) [21]. Some studies have also indicated a potential link between obesity and the occurrence of salivary gland tumors. Suba et al. found that obesity was more prevalent among salivary gland tumor patients than in the control group (p < 0.001) [22]. Leopard et al. observed a significantly higher incidence of adenoid cystic carcinoma in areas with increased obesity in the Welsh population (p = 0.028) [23]. Forrest et al. in Canada reported that an obese BMI was associated with an almost 40% increased risk of salivary gland cancer [24].
A study by Kuzenko et al. indicated that WT has an inflammatory etiology [6]. Obesity as inflammatory induce factor may be one of the triggers of WT development. Additionally, a reduction in the body’s endogenous antioxidant levels as a consequence of an unhealthy diet may also be a contributing factor. Kadletz et al. showed that WT’s patients had a significantly higher BMI in comparison to patients with other benign parotid gland tumors (29.1 vs. 26.2, p < 0.0001) [15]. Similar findings were observed in this study (27.17 vs. 25.62 p < 0.001). However, there was no correlation between the multifocal occurrence of WT in one parotid gland or bilateral parotid occurrence, depending on the patient’s BMI. Conversely, there was a trend towards a higher risk of extraparotid WT localization in patients with a higher BMI (p = 0.08). This phenomenon can probably be explained by a more intense local inflammatory process taking place in the white adipose tissue of the neck in the course of obesity. Further evidence that nutrition may play a role in the development of WT is provided by the fact that the prevalence of WT in the African population is very low [25]. In some epidemiological studies, for example in Uganda, no cases of WT were observed [26]. The incidence of obesity and overweight in the adult population of Uganda is 9.3% and 14.6%, respectively [27]. In contrast, research by Saravakos et al. has identified WT as the most common salivary gland tumor [10]. This study was conducted in Germany, where the prevalence of obesity and overweight in the adult population is 19% and 34.5%, respectively [27].
A well-documented factor that influences the development of WT is smoking cigarettes [28]. The current study found that an increase in the number of cigarettes smoked was associated with a significantly elevated risk of a parotid gland tumor being WT, with an odds ratio from 5.13 to 34.52. In addition, the correlation between cigarette smoking and the risk of bilateral WT was observed, but not for multifocal WT in one parotid gland. Cigarette smoke increases the production of reactive oxygen species (ROS), including H2O2 and O2-. Among the numerous constituents of cigarette smoke, there are DNA-binding agents that have been shown to cause DNA damage, which tends to accumulate, particularly in the mitochondria [29]. The study by Lewis et al. identified an elevated prevalence of the 4977 bp deletion in the mitochondrial genome in smokers and in the oncocytic tumor cells of the WT population [29].
The question of whether mtDNA damage in WT is solely a direct result of cigarette smoke is open to debate. However, smokers tend to consume diets that are less nutritionally balanced and contain fewer dietary antioxidants, and they also consume more alcohol than non-smokers [30]. The reduction in exogenous antioxidants, in conjunction with cigarette smoke, could significantly contribute to increased oxidative damage to mtDNA and more deletions within the parotid gland. Moreover, the results of an experimental study by Yang et al. on mice indicated that the cigarette smoke exposure could disrupt the homeostasis of cholesterol and bile acid metabolism within the liver and subsequently influence the composition and diversity of the gut microbiota. Furthermore, cigarette smoke caused insulin resistance in the livers of mice on a high-fat diet [31].
Furthermore, smoking has been linked to an increased risk of other cancers of the head and neck region. This relationship was observed with greater prevalence in the WT group (p = 0.004). A total of 13 patients in the WT tumor group exhibited concomitant other cancers. The most prevalent cancers were oral squamous cell carcinomas (OSCCs) (nine cases), skin cancers (four cases), and lip cancer (one case). In one patient, a synchronous tumor-to-tumor metastasis of skin cancer was identified in the WT of the parotid gland [8]. The majority of WTs were identified metachronically during the oncological follow-up of patients with OSCC. Nevertheless, it should be noted that abnormal 18F-fluorodeoxyglucose (FDG) uptake in PET/CT is a typical feature of WTs and may suggest the presence of metastatic lymph nodes in synchronous appearance with OSCC (Figure 3) [5].
Another factor associated with WT appearance was old age of patients (p < 0.001). In this study, based on multivariate analysis, each additional year of life increased the odds that a benign tumor located in the parotid gland was a WT by 9.4% (OR = 1.094). The proportion of senescent cells in tissues and organs increases with age, contributing to both the aging process and the development of age-related diseases (ARDs). Despite remaining in the G1 phase of the cell cycle, these cells exhibit active intracellular metabolism, as evidenced by the secretion of proteins such as inflammatory cytokines. The senescence-associated secretory phenotype (SASP) is a phenotype associated with senescent cells that secrete high levels of inflammatory cytokines, immune modulators, growth factors, and proteases. These include interleukin 1β (IL1β), IL6, IL8, and plasminogen activator inhibitor 1 (PAI-1), among others [14,32,33]. Studies have demonstrated that SASP factors can contribute to the development of ARD, promote oncogenesis, and facilitate tumor growth while enhancing tissue repair and regeneration [32,34,35].
The gold standard for the treatment of WT is surgical removal of the tumor from the parotid gland. The extent of the surgical procedure is frequently contingent upon the location, size, and potential multifocality of the lesion. For single tumors classically located in the tail of the parotid gland, extracapsular dissection (ECD) and partial parotidectomy have been demonstrated to provide good treatment results. In contrast, multifocal WTs in the superficial lobe can also be treated by ECD. However, in most cases, due to their close proximity to each other in the parotid gland, they are treated by partial lateral or lateral (superficial) parotidectomy. In the case of multifocal lesions involving both lobes of the parotid gland, total parotidectomy with facial nerve preservation is the recommended treatment [36]. Furthermore, in the event that the tumor is situated in the tail of the parotid gland, in the computed tomography (CT) or magnetic resonance imaging (MRI) scans, the level II neck lymph nodes should be evaluated due to the potential for the presence of foci of extraparotid WTs.
In addition to surgical procedures, there are several non-surgical methods for treating WT. These include microwave ablation (MWA), radiofrequency ablation (RFA), and ultrasound-guided ethanol sclerotherapy (UGES) [36,37,38,39,40].
These non-surgical options demonstrate considerable potential, as evidenced by their effectiveness. They could significantly alter the treatment of WT in the future. However, long-term prospective outcome studies are needed to establish their proper role before they can be widely adopted for WT treatment.
In certain cases of WT, due to the low risk of malignant transformation, which is confirmed by FNAC and the patient’s numerous comorbidities that exclude general anesthesia, a “wait-and-see” policy can be applied. WT is characterized by slow growth, which further decreases after the patient reaches 75 years of age [41]. One marker that assesses the growth of WT is Ki-67. The expression of the Ki-67 proliferation marker, which detects all phases of the cell cycle except G0, is known to predict disease outcome in many human malignancies [6]. In most cases, the Ki-67 labeling index in WT is less than 5%, and its increase may be indicative of malignant transformation [42,43].

5. Study Limitations

This study is limited by its retrospective analysis of the clinical features of patients operated on for benign epithelial parotid tumors at a single clinical center. Additionally, our study group is relatively small and has not been compared with the standard population. The next variable that may influence the overall results is the human-performed collection of medical data with BMI analysis and its interpretation. Due to the retrospective nature of this study and the limited data available to assess patients’ rates of metabolic syndrome-associated comorbidities such as lipoprotein (HDL, LDL), total serum cholesterol, triglyceride, glycated haemoglobin, gamma-glutamyl transpeptidase, aspartate transaminase, alanine transaminase, fibrinogen, C-reactive protein and erythrocyte sedimentation rate were not included in the analysis.
Another concern is the use of BMI in this study to assess the potential impact on the development of chronic inflammation. Currently, obesity is defined by an elevated BMI, which is typically a result of excess adipose tissue. Nevertheless, insulin resistance and inflammation have been documented in individuals with a normal BMI. Conversely, a minority of individuals with an elevated BMI are metabolically healthy. Consequently, the current definition of obesity based on BMI has recently been called into question, and BMI may be inadequate for identifying patients with adipose tissue inflammation [44].
A future prospective study with multivariate analysis assessing the impact of laboratory tests involved in the pro-inflammatory cascade in relation to BMI, nutritional status, and dietary intake would increase the reliability of the evidence for an inflammatory etiology of WT.

6. Conclusions

This study supports the multifactorial etiology of WT development. Among these factors, smoking, advanced age, and obesity have been identified as contributing to the development of WT potentially due to chronic inflammation, which is linked to obesity (Figure 4). The chronic inflammation observed in obese patients may exacerbate the risk of WT, as evidenced by the higher levels of obesity in the younger population of patients with WT and the increase in the incidence of this tumor observed in the populations of developed countries. It is also appropriate to categorize this disease as an age-associated disease (ARD) given the significantly higher incidence observed in individuals over the age of 60. This may be a consequence of the SASP of senescent cells, which are known to produce a range of pro-inflammatory cytokines. Furthermore, the incidence of bilateral WTs demonstrated a positive correlation with the quantity of cigarette smoking. However, multifocal WTs in a single parotid gland were not found to be associated with the amount of cigarette smoking.

Author Contributions

Conceptualization, M.G., K.G. and G.W.-P.; methodology, M.G., J.B. and K.G.; software, M.G., A.H., J.K. and A.W.; validation, M.G. and G.W.-P.; formal analysis, M.G. and K.G.; investigation, M.G., P.S., A.H., J.K., A.W. and K.G.; resources, M.G.; data curation, M.G., K.G. and T.M.; writing—original draft preparation, M.G., J.B. and K.G., writing—review and editing, M.G. and G.W.-P.; visualization M.G., J.B., T.M. and P.S.; supervision, G.W.-P. and M.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Jagiellonian University (No: 122.6120.287.2016).

Informed Consent Statement

Patient consent was waived as all personal information remained confidential.

Data Availability Statement

Restrictions apply to the availability of these data. The data were obtained from patients treated at the Department of Cranio-Maxillofacial Surgery, Cracow, Poland, and cannot be shared in accordance with the General Data Protection Regulation (EU) 2016/679.

Acknowledgments

We thank Łukasz Deryło for their statistical analysis.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bonanthaya, K.; Panneerselvam, E.; Manuel, S.; Kumar, V.V.; Rai, A. Oral and Maxillofacial Surgery for the Clinician; Springer: Singapore, 2021; pp. 958–959. [Google Scholar]
  2. Albrecht, H.; Arzt, L. Beiträge zur Frage der Gewebsveirrung. Papilläre Cystadenome in Lymphdrüsen. Frankf. Z. Pathol. 1910, 4, 47–69. [Google Scholar]
  3. Warthin, A.S. Papillary cystadenoma lymphomatosum. A rare teratoid of the parotid gland region. J. Cancer Res. 1929, 13, 116–125. [Google Scholar]
  4. Xu, W.; Lu, H.; Zhu, Y.; Ruan, M.; Zhang, C.; Yang, W.; Liu, S. Warthin’s tumour in oral and maxillofacial regions: An 18-year retrospective study of 1084 cases in an eastern-Chinese population. Int. J. Oral Maxillofac. Surg. 2018, 47, 913–917. [Google Scholar] [CrossRef]
  5. Gontarz, M.; Gąsiorowski, K.; Bargiel, J.; Marecik, T.; Szczurowski, P.; Zapała, J.; Wyszyńska-Pawelec, G. Extraparotid Warthin Tumors Imitating Metastasis of Oral Cancers. Int. Arch. Otorhinolaryngol. 2021, 26, e278–e280. [Google Scholar] [CrossRef] [PubMed]
  6. Kuzenko, Y.V.; Romanuk, A.M.; Dyachenko, O.O.; Hudymenko, O. Pathogenesis of Warthin’s tumors. Interv. Med. Appl. Sci. 2016, 8, 41–48. [Google Scholar] [CrossRef]
  7. Seifert, G.; Heckmayr, M.; Donath, K. Carcinome in Papillären Cystadenolymphomen der Parotis Definition und Differentialdiagnose [Carcinomas in papillary cystadenolymphomas of the parotid gland--definition and differential diagnosis (author’s transl)]. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 1977, 90, 25–36. [Google Scholar] [CrossRef]
  8. Gontarz, M.; Gałązka, K.; Gąsiorowski, K.; Bargiel, J.; Marecik, T.; Szczurowski, P.; Wyszyńska-Pawelec, G. Tumor-to-Tumor Metastasis: Dissemination of Cutaneous Squamous Cell Carcinoma Involving Parotid Warthin Tumor—Case Report. Diseases 2024, 12, 140. [Google Scholar] [CrossRef]
  9. Laco, J.; Celakovsky, P.; Kalfert, D.; Hornychova, H.; Rybnikar, T.; Ryska, A. Tumor-to-tumor metastasis: Warthin tumor as a recipient of lung carcinoma and of renal carcinoma—Report of two cases. Pathol. Res. Pract. 2010, 206, 458–462. [Google Scholar] [CrossRef]
  10. Saravakos, P.; Kourtidis, S.; Hartwein, J.; Preyer, S. Parotid Gland Tumors: A Multicenter Analysis of 1020 Cases. Increasing Incidence of Warthin’s Tumor. Indian J. Otolaryngol. Head Neck Surg. 2022, 74 (Suppl. 2), 2033–2040. [Google Scholar] [CrossRef]
  11. Franzen, A.M.; Kaup Franzen, C.; Guenzel, T.; Lieder, A. Increased incidence of Warthin tumours of the parotid gland: A 42-year evaluation. Eur. Arch. Otorhinolaryngol. 2018, 275, 2593–2598. [Google Scholar] [CrossRef]
  12. Gontarz, M.; Bargiel, J.; Gąsiorowski, K.; Marecik, T.; Szczurowski, P.; Zapała, J.; Wyszyńska-Pawelec, G. Epidemiology of Primary Epithelial Salivary Gland Tumors in Southern Poland-A 26-Year, Clinicopathologic, Retrospective Analysis. J. Clin. Med. 2021, 10, 1663. [Google Scholar] [CrossRef] [PubMed]
  13. Aga, M.; Kondo, S.; Yamada, K.; Sawada-Kitamura, S.; Yagi-Nakanishi, S.; Endo, K.; Wakisaka, N.; Murono, S.; Kawano, M.; Yoshizaki, T. Warthin’s tumor associated with IgG4-related disease. Auris Nasus Larynx 2013, 40, 514–517. [Google Scholar] [CrossRef] [PubMed]
  14. Aoki, R.; Tanaka, T. Pathogenesis of Warthin’s Tumor: Neoplastic or Non-Neoplastic? Cancers 2024, 16, 912. [Google Scholar] [CrossRef] [PubMed]
  15. Kadletz, L.; Grasl, S.; Perisanidis, C.; Grasl, M.C.; Erovic, B.M. Rising incidences of Warthin’s tumors may be linked to obesity: A single-institutional experience. Eur. Arch. Otorhinolaryngol. 2019, 276, 1191–1196. [Google Scholar] [CrossRef]
  16. World Obesity Federation. Global trends in obesity. In Obesity: Missing the 2025 Global Targets; Trends, Costs and Country Reports; World Obesity Federation: London, UK, 2020; pp. 16–33. [Google Scholar]
  17. OECD. OECD Health Policy Studies. The Heavy Burden of Obesity: The Economics of Prevention; OECD: Paris, France, 2019; p. 256. [Google Scholar]
  18. Hill, J.H.; Solt, C.; Foster, M.T. Obesity associated disease risk: The role of inherent differences and location of adipose depots. Horm. Mol. Biol. Clin. Investig. 2018, 33, 20180012. [Google Scholar] [CrossRef]
  19. Ostrowska, L.; Smarkusz-Zarzecka, J.; Gornowicz, A.; Lendzion, K.; Zyśk, B.; Pogodziński, D. Analysis of Selected Salivary Adipokines and Cytokines in Patients with Obesity-A Pilot Study. Int. J. Mol. Sci. 2023, 24, 4145. [Google Scholar] [CrossRef]
  20. Kolb, R.; Sutterwala, F.S.; Zhang, W. Obesity and cancer: Inflammation bridges the two. Curr. Opin. Pharmacol. 2016, 29, 77–89. [Google Scholar] [CrossRef]
  21. Lehmann, A.P.; Nijakowski, K.; Swora-Cwynar, E.; Łuczak, J.; Czepulis, N.; Surdacka, A. Characteristics of salivary inflammation in obesity. Pol. Arch. Intern. Med. 2020, 130, 297–303. [Google Scholar] [CrossRef]
  22. Suba, Z.; Barabás, J.; Szabó, G.; Takács, D.; Ujpál, M. Increased prevalence of diabetes and obesity in patients with salivary gland tumors. Diabetes Care 2005, 28, 228. [Google Scholar] [CrossRef]
  23. Leopard, D.; El-Hitti, E.; Puttasiddaiah, P.; Mcleod, R.; Owens, D. Twenty-seven years of primary salivary gland carcinoma in Wales: An analysis of histological subtype and associated risk factors. J. Laryngol. Otol. 2022, 136, 167–172. [Google Scholar] [CrossRef]
  24. Forrest, J.; Campbell, P.; Kreiger, N.; Sloan, M. Salivary gland cancer: An exploratory analysis of dietary factors. Nutr. Cancer 2008, 60, 469–473. [Google Scholar] [CrossRef] [PubMed]
  25. Yaor, M.A. The pattern of presentation of salivary gland tumors in Africa: A review of published reports. Ear Nose Throat J. 2010, 89, E17–E21. [Google Scholar] [PubMed]
  26. Vuhahula, E.A. Salivary gland tumors in Uganda: Clinical pathological study. Afr. Health Sci. 2004, 4, 15–23. [Google Scholar]
  27. Global Obesity Observatory. Available online: https://data.worldobesity.org/ (accessed on 5 August 2024).
  28. Sadetzki, S.; Oberman, B.; Mandelzweig, L.; Chetrit, A.; Ben-Tal, T.; Jarus-Hakak, A.; Duvdevani, S.; Cardis, E.; Wolf, M.S. Smoking and risk of parotid gland tumors: A nationwide case-control study. Cancer 2008, 112, 1974–1982. [Google Scholar] [CrossRef]
  29. Lewis, P.D.; Baxter, P.; Paul Griffiths, A.; Parry, J.M.; Skibinski, D.O. Detection of damage to the mitochondrial genome in the oncocytic cells of Warthin’s tumour. J. Pathol. 2000, 191, 274–281. [Google Scholar] [CrossRef]
  30. Larson, N.I.; Story, M.; Perry, C.L.; Neumark-Sztainer, D.; Hannan, P.J. Are diet and physical activity patterns related to cigarette smoking in adolescents? Findings from Project EAT. Prev. Chronic Dis. 2007, 4, A51. [Google Scholar] [PubMed]
  31. Yang, Y.; Yang, C.; Lei, Z.; Rong, H.; Yu, S.; Wu, H.; Yang, L.; Lei, Y.; Liu, W.; Nie, Y.; et al. Cigarette smoking exposure breaks the homeostasis of cholesterol and bile acid metabolism and induces gut microbiota dysbiosis in mice with different diets. Toxicology 2021, 450, 152678. [Google Scholar] [CrossRef]
  32. Birch, J.; Gil, J. Senescence and the SASP: Many therapeutic avenues. Genes Dev. 2020, 34, 1565–1576. [Google Scholar] [CrossRef] [PubMed]
  33. Watanabe, S.; Kawamoto, S.; Ohtani, N.; Hara, E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci. 2017, 108, 563–569. [Google Scholar] [CrossRef]
  34. Lecot, P.; Alimirah, F.; Desprez, P.Y.; Campisi, J.; Wiley, C. Context-dependent effects of cellular senescence in cancer development. Br. J. Cancer 2016, 114, 1180–1184. [Google Scholar] [CrossRef]
  35. Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75, 685–705. [Google Scholar] [CrossRef] [PubMed]
  36. Quer, M.; Hernandez-Prera, J.C.; Silver, C.E.; Casasayas, M.; Simo, R.; Poorten, V.V.; Guntinas-Lichius, O.; Bradley, P.J.; Tong-Ng, W.; Rodrigo, J.P.; et al. Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. Diagnostics 2021, 11, 1467. [Google Scholar] [CrossRef] [PubMed]
  37. Do, K.; Kawana, E.; Tian, S.; Bigcas, J.L. Treatment of Warthin’s Tumors of the Parotid Gland with Radiofrequency Ablation: A Systematic Review of the Current Literature. Ear Nose Throat J. 2024. [Google Scholar] [CrossRef] [PubMed]
  38. Jin, M.; Fu, J.; Lu, J.; Xu, W.; Chi, H.; Wang, X.; Cong, Z. Ultrasound-guided percutaneous microwave ablation of parotid gland adenolymphoma: A case report. Medicine 2019, 98, e16757. [Google Scholar] [CrossRef]
  39. Tung, Y.C.; Luo, S.D.; Su, Y.Y.; Chen, W.C.; Chen, H.L.; Cheng, K.L.; Lin, W.C. Evaluation of Outcomes following Radiofrequency Ablation for Treatment of Parotid Tail Warthin Tumors. J. Vasc. Interv. Radiol. 2019, 30, 1574–1580. [Google Scholar] [CrossRef]
  40. Mamidi, I.S.; Lee, E.; Benito, D.A.; Li, L.; Goodman, J.F.; Thakkar, P.G.; Joshi, A. Ultrasound-guided ethanol sclerotherapy for non-surgical treatment of Warthin’s tumor. Am. J. Otolaryngol. 2021, 42, 102813. [Google Scholar] [CrossRef]
  41. Schwalje, A.T.; Uzelac, A.; Ryan, W.R. Growth rate characteristics of Warthin’s tumours of the parotid gland. Int. J. Oral. Maxillofac. Surg. 2015, 44, 1474–1479. [Google Scholar] [CrossRef]
  42. Faur, A.C.; Sas, I.; Motoc, A.G.; Cornianu, M.; Zamfir, C.; Lazăr, D.C.; Folescu, R. Ki-67 and p53 immunostaining assessment of proliferative activity in salivary tumors. Rom. J. Morphol. Embryol. 2015, 56, 1429–1439. [Google Scholar]
  43. Shou, L.; Chen, X.; Yang, J.; Jiang, Y. Malignant transformation of Warthin’s tumor into squamous cell carcinoma: A case report. Oncol. Lett. 2022, 24, 201. [Google Scholar] [CrossRef]
  44. Iyengar, N.M.; Gucalp, A.; Dannenberg, A.J.; Hudis, C.A. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J. Clin. Oncol. 2016, 34, 4270–4276. [Google Scholar] [CrossRef]
Jcm 13 04935 g001
Figure 1. Flow chart of the study population.
Figure 1. Flow chart of the study population.
Jcm 13 04935 g001
Jcm 13 04935 g002
Figure 2. Clinical view of a patient with bilateral WTs and BMI 35.5 kg/m2 who smokes more than 20 cigarettes per day. Extraparotid localization in cervical levels II and III is visible on the left side.
Figure 2. Clinical view of a patient with bilateral WTs and BMI 35.5 kg/m2 who smokes more than 20 cigarettes per day. Extraparotid localization in cervical levels II and III is visible on the left side.
Jcm 13 04935 g002
Jcm 13 04935 g003
Figure 3. PET/CT scan: horizontal view with WT in the tail of the left parotid gland in a patient following resection of squamous cell carcinoma of the floor of the mouth. Abnormal, high FDG uptake on PET/CT in WT may be a misleading indication of lymph node metastasis (red arrow).
Figure 3. PET/CT scan: horizontal view with WT in the tail of the left parotid gland in a patient following resection of squamous cell carcinoma of the floor of the mouth. Abnormal, high FDG uptake on PET/CT in WT may be a misleading indication of lymph node metastasis (red arrow).
Jcm 13 04935 g003
Jcm 13 04935 g004
Figure 4. Graphic summarizing the multifactorial etiology of developing WT.
Figure 4. Graphic summarizing the multifactorial etiology of developing WT.
Jcm 13 04935 g004
Table 1. Clinical differences between the groups of patients with WT and other epithelial benign parotid tumors.
Table 1. Clinical differences between the groups of patients with WT and other epithelial benign parotid tumors.
ParameterWarthin’s Tumor (n = 155)Other Benign Tumors (n = 310)p
BMI [kg/m2]Average (SD)27.3 (3.84)25.52 (4.42)p < 0.001
Median (quartile)27.17 (24.82–29.61)25.62 (22.21–27.64)
Range18.34–40.916.65–40.51
n155310
Age (years)Average (SD)64.37 (8.75)48.34 (16.72)p < 0.001
Median (quartile)65 (59–70)49 (36–61)
Range42–8711–85
n155310
SexMale99 (63.87%)111 (35.81%)p < 0.001
Female56 (36.13%)199 (64.19%)
Diameter of the tumor [mm]Average (SD)25.03 (10.67)27.57 (10.48)p = 0.012
Median (quartile)23.5 (18–32)26 (20–35)
Range4–798–65
n154304
Site of the tumorSuperficial lobe128 (82.58%)261 (84.19%)p < 0.001
Deep lobe19 (12.26%)49 (15.81%)
Neck lymph nodes8 (5.16%)0 (0.00%)
Multifocal tumor in the parotid glandNo129 (83.23%)300 (96.77%)p < 0.001
Yes19 (12.26%)10 (3.23%)
No data7 (4.52%)0 (0.00%)
Facial nerve dysfunctionNo140 (90.32%)260 (83.87%)p = 0.08
Yes15 (9.68%)50 (16.13%)
Other head and neck cancerNo141 (90.97%)303 (97.74%)p = 0.004
Yes13 (8.39%)7 (2.26%)
No data1 (0.65%)0 (0.00%)
Cigarette smokingNon-smoker26 (16.77%)238 (76.77%)p < 0.001
Cigarettes <10/day 25 (16.13%)44 (14.19%)
Cigarettes 10–20/day 46 (29.68%)17 (5.48%)
Cigarettes >20/day52 (33.55%)10 (3.23%)
Former smoker6 (3.87%)1 (0.32%)
SD—Standard deviation; BMI: Body Mass Index.
Table 2. Multivariable logistic regression describing risk factors for WT in a group of patients with benign epithelial parotid tumors.
Table 2. Multivariable logistic regression describing risk factors for WT in a group of patients with benign epithelial parotid tumors.
FeatureOR95%CIp-Value
BMI (kg/m2)1.1211.0391.210.003
Age (years)1.0941.0641.125<0.001
SexMale1ref.
Female0.4050.2160.7610.005
Tumor diameter (mm)0.9790.9491.010.179
Site of the tumorSuperficial lobe1ref.
Deep lobe0.5680.2351.3750.21
Neck lymph nodes------------
Multifocal tumor in the parotid glandNo1ref.
Yes3.0260.78911.6070.107
Other head and neck cancerNo1ref.
Yes5.7131.08130.2040.04
Cigarette smokingNon-smoker1ref.
Cigarettes <10/day 5.1362.30711.431<0.001
Cigarettes 10–20/day 14.0145.95532.975<0.001
Cigarettes >20/day34.52612.26297.215<0.001
Former smoker9.3360.94692.110.056
Duration of symptoms0.9780.9640.9910.001
ref.—reference level; OR—odd ratio; CI—confidence interval.
Table 3. Analysis of the relationship between patients with unifocal WT and multifocal WT in the parotid gland.
Table 3. Analysis of the relationship between patients with unifocal WT and multifocal WT in the parotid gland.
ParameterMultifocal WT in the Parotid Glandp-Value
No (n = 129)Yes (n = 19)
BMI (kg/m2)Average (SD)27.33 (3.77)26.23 (4.16)p = 0.497
Median (quartile)27.17 (24.91–29.35)26.7 (22.46–29.77)
Range18.51–40.918.34–32.72
n12919
Cigarette smokingNon-smoker23 (17.83%)3 (15.79%)p = 0.315
Cigarettes <10/day24 (18.60%)1 (5.26%)
Cigarettes 10–20/day38 (29.46%)5 (26.32%)
Cigarettes >20/day38 (29.46%)10 (52.63%)
Former smoker6 (4.65%)0 (0.00%)
Age (years)Average (SD)64.43 (8.58)65.68 (7.73)p = 0.269
Median (quartile)65 (59–70)67 (63.5–70)
Range42–8742–79
n12919
SexMale82 (63.57%)13 (68.42%)p = 0.876
Female47 (36.43%)6 (31.58%)
Table 4. Analysis of the relationship between patients with bilateral and unilateral WTs.
Table 4. Analysis of the relationship between patients with bilateral and unilateral WTs.
ParameterUnilateral (n = 134)Bilateral (n = 21)p-Value
BMI (kg/m2)Average (SD)27.34 (3.91)27.02 (3.41)p = 0.786
Median (quartile)27.35 (24.82–29.77)26.83 (25.35–29.32)
Range18.34–40.920.28–34.06
n13421
Cigarette smokingNon-smoker25 (18.66%)1 (4.76%)p = 0.038
Cigarettes <10/day24 (17.91%)1 (4.76%)
Cigarettes 10–20/day41 (30.60%)5 (23.81%)
Cigarettes >20/day39 (29.10%)13 (61.90%)
Former smoker5 (3.73%)1 (4.76%)
Age (years)Average (SD)64.13 (9)65.86 (7.01)p = 0.584
Median (quartile)65 (59–70)65 (60–67)
Range42–8758–86
n13421
SexMale84 (62.69%)15 (71.43%)p = 0.595
Female50 (37.31%)6 (28.57%)
Table 5. Analysis of the relationship between patients with intraparotid and extraparotid WTs.
Table 5. Analysis of the relationship between patients with intraparotid and extraparotid WTs.
ParameterParotid WT
(n = 147)		Extraparotid WT
(n = 8)		p-Value
BMI [kg/m2]Average (SD)27.17 (3.83)29.63 (3.5)p = 0.08
Median (quartile)27.16 (24.45–29.4)29.94 (27.76–30.77)
Range18.34–40.924.82–35.51
n1478
Cigarette smokingNon-smoker26 (17.69%)0 (0.00%)p = 0.319
Cigarettes <10/day25 (17.01%)0 (0.00%)
Cigarettes 10–20/day43 (29.25%)3 (37.50%)
Cigarettes >20/day47 (31.97%)5 (62.50%)
Former smoker6 (4.08%)0 (0.00%)
Age (years)Average (SD)64.6 (8.49)60.12 (12.73)p = 0.095
Median (quartile)65 (59.5–70)58.5 (54–63.5)
Range42–8742–86
n1478
SexMale94 (63.95%)5 (62.50%)p = 1
Female53 (36.05%)3 (37.50%)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gontarz, M.; Bargiel, J.; Gąsiorowski, K.; Marecik, T.; Szczurowski, P.; Hramyka, A.; Kuczera, J.; Wieczorkiewicz, A.; Wyszyńska-Pawelec, G. Could Obesity Be Related to the Increasing Incidence of Warthin Tumors? J. Clin. Med. 2024, 13, 4935. https://doi.org/10.3390/jcm13164935

AMA Style

Gontarz M, Bargiel J, Gąsiorowski K, Marecik T, Szczurowski P, Hramyka A, Kuczera J, Wieczorkiewicz A, Wyszyńska-Pawelec G. Could Obesity Be Related to the Increasing Incidence of Warthin Tumors? Journal of Clinical Medicine. 2024; 13(16):4935. https://doi.org/10.3390/jcm13164935

Chicago/Turabian Style

Gontarz, Michał, Jakub Bargiel, Krzysztof Gąsiorowski, Tomasz Marecik, Paweł Szczurowski, Andrei Hramyka, Joanna Kuczera, Agata Wieczorkiewicz, and Grażyna Wyszyńska-Pawelec. 2024. "Could Obesity Be Related to the Increasing Incidence of Warthin Tumors?" Journal of Clinical Medicine 13, no. 16: 4935. https://doi.org/10.3390/jcm13164935

APA Style

Gontarz, M., Bargiel, J., Gąsiorowski, K., Marecik, T., Szczurowski, P., Hramyka, A., Kuczera, J., Wieczorkiewicz, A., & Wyszyńska-Pawelec, G. (2024). Could Obesity Be Related to the Increasing Incidence of Warthin Tumors? Journal of Clinical Medicine, 13(16), 4935. https://doi.org/10.3390/jcm13164935

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop